IP Library Granted Patent US 9,381,218
Granted Patent B2
US 9,381,218 · App. 14/223,833 · Granted Jul 5, 2016

Artificial skeletal material and constructs formed therefrom

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,218
App. No.
14/223,833
Granted
Jul 5, 2016
Kind
B2
Abstract

A bioresorbable skeletal construct member formed from an osteoinductive composition comprising autogenic bone and an extracellular matrix (ECM) material, the construct member being configured to induce osteoanagenesis and angiogenesis when implanted proximate endogenous bone and tissue.

Claims (9)

1. A prosthetic skeletal construct, comprising:

a bioresorbable construct comprising an osteoinductive composition, said osteoinductive composition comprising autogenic bone marrow and acellular extracellular matrix (ECM) from a mammalian tissue source, said construct member being configured to induce osteoanagenesis and angiogenesis when said construct member is implanted proximate endogenous bone and tissue.

2. The skeletal construct of claim 1 , wherein said osteoinductive composition further comprises polyurethane urea.

3. The skeletal construct of claim 1 , wherein said osteoinductive composition comprises at least 20% of said ECM.

4. The skeletal construct of claim 1 , wherein said osteoinductive composition comprises at least 50% of said ECM.

5. The skeletal construct of claim 1 , wherein said comprises small intestine submucosa (SIS).

6. The skeletal construct of claim 1 , wherein said mammalian tissue source comprises an adolescent mammalian tissue source.

7. The skeletal construct of claim 1 , wherein said osteoinductive composition further comprises at least one exogenously added biologically active agent.

8. The skeletal construct of claim 7 , wherein said biologically active agent comprises an osteogenic agent selected from the group consisting of TGF-β1, TGF-β2, TGF-β3, TGF-β4, and TGF-β5.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070482/0040 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
SECURITY INTEREST Recorded Feb 15, 2017
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 041266/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2016
From: MATHENY, ROBERT G
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 037762/0049 →